MiniMed Fit (patch pump)

The MiniMed Fit is MiniMed's tubeless "patch" insulin pump — its bid to compete in the patch-pump category that includes Insulet's Omnipod.⁵ It is described as a tubeless, patch-style system worn directly on the body.²

A note on the name: this is the diabetes business that used to be Medtronic Diabetes. It was carved out as MiniMed Group, Inc., which listed on Nasdaq (ticker MMED) in March 2026.³ The product and the pipeline are the same; the company badge on them is now MiniMed.

Form factor and wear

Unlike Insulet's fully disposable Omnipod (comparison per trade-press previews), the Fit is described as using a semi-durable, two-piece design: a rechargeable, reusable electronics base plus a disposable reservoir-and-adhesive component (design specifics not in any fetched MiniMed-original text).⁶ MiniMed is reported to supply two rechargeable batteries, each rated to last longer than a full wear cycle, so one charges while the other is in use (battery specifics not in fetched text).⁷ The reservoir holds 300 units of insulin and the device is rated for up to 7-day wear.⁶ An earlier plan to buy patch-pump maker EOFlow for about $738 million was terminated in December 2023 amid a patent dispute involving Insulet.⁸

Infusion, occlusion detection and reliability

Detailed specifications for the cannula/infusion set and the occlusion-detection system have not been published, and there is no peer-reviewed precision or reliability data yet.² The controlling Vivera algorithm has completed US pivotal-trial enrollment according to MiniMed’s September update, so real-world performance, alarms and occlusion handling remain unproven.⁹ These figures should be read as manufacturer-stated, pre-clearance claims.

CGM, algorithm and DIY compatibility

The Fit is built to share the same algorithm and sensor ecosystem as the tubed MiniMed Flex.⁹ That means it is intended to run on MiniMed's Vivera algorithm — described as a third-generation full closed-loop system with optional meal bolusing (meal-mode specifics per trade-press reporting; not in fetched MiniMed-original text) — alongside the Simplera Sync sensor and the Abbott-built Instinct sensor.⁶ The Simplera Sync CGM was FDA-approved for MiniMed's automated insulin delivery system in April 2025.¹⁰ As a closed, proprietary system as described in previews, the Fit has no announced DIY/open-source-loop compatibility (explicit incompatibility not stated in fetched text).

Vivera is the part of this stack with any human data at all, and even that is thin. Conference reporting from ADA 2026 describes an adult feasibility study in which Vivera reached a mean time-in-range of 73.8% with no user input at all, rising to 82.3% when users chose to count carbs (figures and study design as reported; neither re-verified against a primary session source in this review).¹ Read those numbers carefully: a feasibility study is small, short and not designed to prove anything — US pivotal-trial enrollment is now complete according to MiniMed, and none of this was measured on the Fit patch pump itself.

Phone bolusing

MiniMed's next-generation pumps are moving to app-only control: the sibling MiniMed Flex has no screen and is operated entirely from a phone, and the Fit is expected to follow the same phone-first model — implying phone bolusing.¹¹ The dedicated app, however, is unreleased and its features unverified.

Access and development

MiniMed announced Fit’s FDA submission on 1 September 2026 and targets full US launch in summer 2027. This supersedes the older fall-submission and 2028 estimates. Submission does not establish clearance, price, final wear specifications or reimbursement.⁴

How to read this pipeline score. Design features and unreported outcomes are editorial projections. Trial entry ages are not an approved age indication. A study result applies only to its studied population and does not establish future commercial performance or access.